Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
17.6 USD | +0.72% | -17.45% | +60.19% |
10/05 | Wedbush Raises Edgewise Therapeutics' PT to $31 From $26, Keeps Outperform Rating | MT |
09/05 | Edgewise Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+60.19% | 163.26Cr | |
+29.78% | 4.82TCr | |
-0.75% | 4.17TCr | |
+44.02% | 4.1TCr | |
-5.31% | 2.88TCr | |
+10.47% | 2.56TCr | |
-22.49% | 1.9TCr | |
+9.06% | 1.29TCr | |
+28.64% | 1.2TCr | |
-2.42% | 1.18TCr |
- Stock Market
- Equities
- EWTX Stock
- News Edgewise Therapeutics, Inc.
- Wedbush Lowers Edgewise Therapeutics' PT to $23 From $27, Sees 2024 as 'Critical' Year; Keeps Outperform Rating